A Phase 1/2 interventional study of GEN1107 in Endometrial Cancer, Ovarian Cancer and Triple Negative Breast Cancer, sponsored by Genmab. Terminated at 7 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by Genmab · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 715 studies in Endometrial Neoplasms with a site in United States — 195 open to participants now, 284 under way, 22 of them phase 3. Endometrial Neoplasms · United States.
Among the 715 studies in Endometrial Neoplasms with a site in United States, this one is the 399th largest by enrollment of the 591 interventional ones that give a count, is one of 46 that started in 2024, is one of 85 in phase 1/2, and was the 567th registered.
1,429 studies on the registry are indexed under Endometrial Neoplasms; 470 are open to participants now.
Browse Endometrial Neoplasms studies →195 of the 715 studies in Endometrial Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Pfizer · Sites in United States, Australia, China and 2 more countries
Ages 18+ · Women only
University of Oklahoma · Sites in United States
Ages 18+ · Women only
Crescent Biopharma, Inc. · Sites in United States
Ages 18+
Sutro Biopharma, Inc. · Sites in United States
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18+ · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
715 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 277 · Phase 2 264 · Phase 3 40 · Phase 4 3
First in 1987; this study’s year is marked. 46 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 33 is below the median of 71 across 1,029 interventional studies indexed under Endometrial Neoplasms.
Median enrollment 60 across the 591 interventional studies, 148 across the 100 observational. Of the 386 that completed or were terminated, 132 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
275 of 715 have an industry lead sponsor. The 10 most frequent:
Genmab is the lead sponsor of 72 studies on the registry; 15 are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 14 (61%) have results posted.
Genmab has 6 studies filed under Endometrial Neoplasms — fewer than ten, so there is no comparison to draw.
95 of the studies in Endometrial Neoplasms with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03785288Phase 3Kara Romano, MDVaginal Cuff Brachytherapy Fractionation Study | 2027-01-30 |
| NCT05173987Phase 3Merck Sharp & Dohme LLCStudy of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15) | 2027-05-27 |
| NCT07044336Phase 3AstraZenecaPuxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) | 2027-10-15 |
| NCT05256225Phase 3National Cancer Institute (NCI)Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma | 2027-10-31 |
| NCT02285192Memorial Sloan Kettering Cancer CenterPositron Lymphography Via Intracervical 18F-FDG Injection for Pre-surgical Lymphatic Mapping in Stage IB1 Cervical Cancer and High-grade Endometrial Cancer | 2026-11 |
Add all 95 to your calendar (.ics) → With an account.
Among the 715 studies in Endometrial Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a global, open-label, multicenter Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of GEN1107 (PRO1107) in participants with advanced solid tumors. This study consists of 2 parts, Part A: dose escalation and dose level expansion, and Part B: tumor specific expansion.
This is a Phase 1/2 study of GEN1107, a protein tyrosine K 7 (PTK7) targeted antibody-drug conjugate (ADC), to evaluate the safety, tolerability, PK, and antitumor activity of GEN1107 in participants with advanced solid tumors, including ovarian cancer, endometrial cancer, triple negative breast cancer, non-small cell lung cancer, gastroesophageal cancer, and urothelial cancer. This study consists of 2 parts, Part A: Dose Escalation and Dose Level Expansion and Part B: Tumor Specific Expansion.
In Part A, GEN1107 will be administered in different dosing regimens via intravenous (IV) infusion.
Part B will be initiated at a dose level based on a comprehensive analysis of safety, tolerability, clinical PK, pharmacodynamics (PD) and activity data from Part A in up to 4 different tumor-specific cohorts of up to 40 participants per cohort.
Participants will continue to receive study treatment until the first instance of disease progression, unacceptable toxicity, investigator decision, consent withdrawal, study termination by the Sponsor, pregnancy, or death.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Part A:
Non-small cell lung cancer (NSCLC)
Part B:
Participants must have a histologically or cytologically confirmed metastatic or unresectable solid as specified below:
Exclusion Criteria
Additional protocol defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GEN1107 monotherapy in escalating doses in Part A and at the dose level in Part B.
Drug: GEN1107
IV infusion of GEN1107
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
A TEAE was defined as any adverse event (AE) with an onset date or worsening grade within the on-treatment period. An AE was defined as any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which did not necessarily have a causal relationship with this treatment. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
Time frame: Up to approximately 1 year, 7 months
Number of Participants With Dose Limiting Toxicities (DLTs)
A DLT was defined as any of the following during the DLT evaluation period (up to 28 days) if considered not clearly and incontrovertibly due to the underlying disease or extraneous causes by either the Investigator or the Sponsor: any death not clearly due to the underlying disease or extraneous causes, ≥ Grade 3 non-hematologic toxicity, with exceptions per protocol, the abnormality indicative of drug-induced liver injury as defined by Hy's Law criteria, Grade 4 anemia or Grade 3 anemia lasting \>7 days (transfusions permitted), Grade 4 neutropenia lasting \>7 days, Grade 4 thrombocytopenia lasting \>7 days, or ≥ Grade 3 thrombocytopenia with clinically significant bleeding, febrile neutropenia (absolute neutrophil count \[ANC\] \<1000/microliters \[µL\] with a single oral temperature measurement of ≥ 38.3 degrees Celsius \[ºC\] \[101 degrees Fahrenheit \[ºF\]\] or a temperature of ≥ 38ºC \[100.4ºF\] sustained over a 1-hour period).
Time frame: Up to 28 days
Objective Response Rate (ORR)
ORR was defined as the percentage of participants who achieved partial response (PR) or complete response (CR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria as assessed by the investigator. CR was defined as disappearance of all target and non-target tumor lesions, reduction in short axis to \<10 millimeters (mm) in all pathological target and non-target lymph nodes and normalization of tumor marker level (if applicable). PR was defined as ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Confidence interval (CI) is based on the Clopper-Pearson method.
Time frame: Up to approximately 1 year, 7 months
Disease Control Rate (DCR)
DCR was defined as the percentage of participants having stable disease (SD) or achieving a PR or CR per RECIST v1.1 criteria. CI is based on the Clopper-Pearson method.
Time frame: Up to approximately 1 year, 7 months
Progression-free Survival (PFS)
PFS was defined as the time from the start of any study treatment to first documentation of disease progression or to death due to any cause, whichever came first. Data are reported based on Kaplan-Meier estimate.
Time frame: Up to approximately 1 year, 7 months
Duration of Objective Response (DOR)
DOR was defined as the time from the first documentation of an objective tumor response (CR or PR) to the first documentation of tumor progression or to death due to any cause, whichever came first. Data are reported based on Kaplan-Meier estimate.
Time frame: Up to approximately 1 year, 7 months
Area Under the Curve (AUC) of GEN1107 Related Analytes
Plasma samples were taken for analysis of GEN1107 pharmacokinetics. Data are reported for GEN1107 related analytes (total antibody, conjugated monomethyl auristatin E \[MMAE\], unconjugated MMAE).
Time frame: For Q3W Dosing cohorts only: Cycle1 Day 1: pre-dose, end of infusion (EOI), 2, 24, 72,168, 336, and 504 hours post-dose (21 day cycles). For 2Q4W Dosing Cohorts only: Cycle 1 Day 8: pre-2nd dose, EOI, 72, 168, 336, 504 hours post-2nd dose (28 day cycles)
Maximum Concentration (Cmax) of GEN1107 Related Analytes
Plasma samples were taken for analysis of GEN1107 pharmacokinetics. Data are reported for GEN1107 related analytes (total antibody, conjugated MMAE, unconjugated MMAE).
Time frame: Q3W Dosing cohorts only: Cycle1 Day 1:pre-dose, EOI,2,24,72,168,336,504 hours post-dose (21 day cycles), 2Q4W Dosing Cohorts only: Cycle1 Day 1:pre-dose,EOI,72hr post-dose, Cycle 1 Day 8:pre-2nd dose,EOI,72,168,336,504 hours post-2nd dose (28 day cycles)
Time to Maximum Concentration (Tmax) of GEN1107 Related Analytes
Plasma samples were taken for analysis of GEN1107 pharmacokinetics. Data are reported for GEN1107 related analytes (total antibody, conjugated MMAE, unconjugated MMAE).
Time frame: Q3W Dosing cohorts only: Cycle1 Day 1:pre-dose,EOI,2,24,72,168,336,504 hours post-dose (21 day cycles), 2Q4W Dosing Cohorts only:Cycle1 Day 1:pre-dose,EOI,72hr post-dose, Cycle 1 Day 8:pre-2nd dose, EOI,72,168, 336, 504 hours post-2nd dose (28 day cycles)
Apparent Terminal Half-life (t1/2) of GEN1107 Related Analytes
Plasma samples were taken for analysis of GEN1107 pharmacokinetics. Data are reported for GEN1107 related analytes (total antibody, conjugated MMAE, unconjugated MMAE).
Time frame: For Q3W Dosing cohorts only: Cycle1 Day 1: pre-dose, EOI, 2, 24, 72,168, 336, and 504 hours post-dose (21 day cycles), for 2Q4W Dosing Cohorts only: Cycle 1 Day 8: pre-2nd dose, EOI, 72, 168, 336, 504 hours post-2nd dose (28 day cycles)
Trough Concentration (Ctrough) of GEN1107 Related Analytes
Plasma samples were taken for analysis of GEN1107 pharmacokinetics. Data are reported for GEN1107 related analytes (total antibody, conjugated MMAE, unconjugated MMAE). The number of participants analyzed reflects participants with evaluable PK data at the relevant sampling timepoint. Where 0 participants are reported, this indicates that no participants had evaluable data for that parameter/timepoint or that the assessment was not applicable for the dosing regimen.
Time frame: Q3W Dosing cohorts only: Cycle1 Day 1:pre-dose,EOI,2,24,72,168,336, 504 hours post-dose (21 day cycles), 2Q4W Dosing Cohorts only: Cycle1 Day 1:pre-dose,EOI,72hr post-dose, Cycle 1 Day 8:pre-2nd dose,EOI,72,168,336,504 hours post-2nd dose (28 day cycles).
Number of Participants With Cancer Antigen 125 (CA-125) Response Per Gynecological Cancer Intergroup (GCIG) Criteria for Ovarian Cancer
For participants with ovarian cancer, a CA-125 response per the GCIG criteria was defined as a ≥50% reduction in CA-125 levels from baseline. The following must also have applied: CA-125 levels must have been ≥2.0 times the upper limit of normal (ULN) within 2 weeks before starting treatment, and the CA-125 response must have been confirmed and maintained for at least 28 days. The analysis included participants with ovarian cancer who were evaluable for CA-125 response. Evaluable participants had baseline CA-125 ≥2× the upper limit of normal (ULN) within 14 days before the first dose and at least one post-baseline assessment. Participants who did not meet these criteria were excluded from the analysis. For arms with an overall number analyzed of 0, no participants met the protocol-defined evaluability criteria.
Time frame: Up to approximately 1 year, 7 months
| Milestone | Dose Escalation: GEN1107 8 mg/m^2 | Dose Escalation: GEN1107 15 mg/m^2 | Dose Escalation: GEN1107 30 mg/m^2 | Dose Escalation: GEN1107 37.5 mg/m^2 | Dose Escalation: GEN1107 45 mg/m^2 | Dose Escalation: GEN1107 52.5 mg/m^2 | Dose Escalation: GEN1107 60 mg/m^2 | Dose Escalation: GEN1107 30 mg/m^2 2Q4W |
|---|---|---|---|---|---|---|---|---|
| Started | 2 | 2 | 4 | 5 | 6 | 4 | 8 | 2 |
| Received at least 1 dose of treatment | 2 | 2 | 4 | 5 | 6 | 4 | 8 | 2 |
| Completed | 0 | 1 | 2 | 2 | 2 | 1 | 0 | 0 |
| Not completed | 2 | 1 | 2 | 3 | 4 | 3 | 8 | 2 |
| Withdrew: Death | 1 | 1 | 2 | 1 | 3 | 3 | 7 | 2 |
| Withdrew: Study termination by sponsor | 1 | 0 | 0 | 2 | 0 | 0 | 1 | 0 |
| Withdrew: Progressive disease | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
A TEAE was defined as any adverse event (AE) with an onset date or worsening grade within the on-treatment period. An AE was defined as any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which did not necessarily have a causal relationship with this treatment. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
| Participants | Dose Escalation: GEN1107 8 mg/m^2 | Dose Escalation: GEN1107 15 mg/m^2 | Dose Escalation: GEN1107 30 mg/m^2 | Dose Escalation: GEN1107 37.5 mg/m^2 | Dose Escalation: GEN1107 45 mg/m^2 | Dose Escalation: GEN1107 52.5 mg/m^2 | Dose Escalation: GEN1107 60 mg/m^2 | Dose Escalation: GEN1107 30 mg/m^2 2Q4W |
|---|---|---|---|---|---|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 2 | 2 | 4 | 5 | 5 | 4 | 8 | 2 |
A DLT was defined as any of the following during the DLT evaluation period (up to 28 days) if considered not clearly and incontrovertibly due to the underlying disease or extraneous causes by either the Investigator or the Sponsor: any death not clearly due to the underlying disease or extraneous causes, ≥ Grade 3 non-hematologic toxicity, with exceptions per protocol, the abnormality indicative of drug-induced liver injury as defined by Hy's Law criteria, Grade 4 anemia or Grade 3 anemia lasting \>7 days (transfusions permitted), Grade 4 neutropenia lasting \>7 days, Grade 4 thrombocytopenia lasting \>7 days, or ≥ Grade 3 thrombocytopenia with clinically significant bleeding, febrile neutropenia (absolute neutrophil count \[ANC\] \<1000/microliters \[µL\] with a single oral temperature measurement of ≥ 38.3 degrees Celsius \[ºC\] \[101 degrees Fahrenheit \[ºF\]\] or a temperature of ≥ 38ºC \[100.4ºF\] sustained over a 1-hour period).
| Participants | Dose Escalation: GEN1107 8 mg/m^2 | Dose Escalation: GEN1107 15 mg/m^2 | Dose Escalation: GEN1107 30 mg/m^2 | Dose Escalation: GEN1107 37.5 mg/m^2 | Dose Escalation: GEN1107 45 mg/m^2 | Dose Escalation: GEN1107 52.5 mg/m^2 | Dose Escalation: GEN1107 60 mg/m^2 | Dose Escalation: GEN1107 30 mg/m^2 2Q4W |
|---|---|---|---|---|---|---|---|---|
| Number of Participants With Dose Limiting Toxicities (DLTs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
ORR was defined as the percentage of participants who achieved partial response (PR) or complete response (CR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria as assessed by the investigator. CR was defined as disappearance of all target and non-target tumor lesions, reduction in short axis to \<10 millimeters (mm) in all pathological target and non-target lymph nodes and normalization of tumor marker level (if applicable). PR was defined as ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Confidence interval (CI) is based on the Clopper-Pearson method.
| percentage of participants | Dose Escalation: GEN1107 8 mg/m^2 | Dose Escalation: GEN1107 15 mg/m^2 | Dose Escalation: GEN1107 30 mg/m^2 | Dose Escalation: GEN1107 37.5 mg/m^2 | Dose Escalation: GEN1107 45 mg/m^2 | Dose Escalation: GEN1107 52.5 mg/m^2 | Dose Escalation: GEN1107 60 mg/m^2 | Dose Escalation: GEN1107 30 mg/m^2 2Q4W |
|---|---|---|---|---|---|---|---|---|
| Objective Response Rate (ORR) | 0 (0.00 to 84.19) | 0 (0.00 to 84.19) | 0 (0.00 to 60.24) | 0 (0.00 to 52.18) | 0 (0.00 to 52.18) | 0 (0.00 to 70.76) | 28.6 (3.67 to 70.96) | — |
DCR was defined as the percentage of participants having stable disease (SD) or achieving a PR or CR per RECIST v1.1 criteria. CI is based on the Clopper-Pearson method.
| percentage of participants | Dose Escalation: GEN1107 8 mg/m^2 | Dose Escalation: GEN1107 15 mg/m^2 | Dose Escalation: GEN1107 30 mg/m^2 | Dose Escalation: GEN1107 37.5 mg/m^2 | Dose Escalation: GEN1107 45 mg/m^2 | Dose Escalation: GEN1107 52.5 mg/m^2 | Dose Escalation: GEN1107 60 mg/m^2 | Dose Escalation: GEN1107 30 mg/m^2 2Q4W |
|---|---|---|---|---|---|---|---|---|
| Disease Control Rate (DCR) | 50.0 (1.26 to 98.74) | 100.0 (15.81 to 100.00) | 75.0 (19.41 to 99.37) | 100.0 (47.82 to 100.00) | 40.0 (5.27 to 85.34) | 66.7 (9.43 to 99.16) | 71.4 (29.04 to 96.33) | — |
PFS was defined as the time from the start of any study treatment to first documentation of disease progression or to death due to any cause, whichever came first. Data are reported based on Kaplan-Meier estimate.
| months | Dose Escalation: GEN1107 8 mg/m^2 | Dose Escalation: GEN1107 15 mg/m^2 | Dose Escalation: GEN1107 30 mg/m^2 | Dose Escalation: GEN1107 37.5 mg/m^2 | Dose Escalation: GEN1107 45 mg/m^2 | Dose Escalation: GEN1107 52.5 mg/m^2 | Dose Escalation: GEN1107 60 mg/m^2 | Dose Escalation: GEN1107 30 mg/m^2 2Q4W |
|---|---|---|---|---|---|---|---|---|
| Progression-free Survival (PFS) | NA (1.28 to NA) | 4.09 (4.07 to NA) | 2.63 (1.38 to NA) | 7.43 (2.73 to NA) | 1.40 (0.89 to NA) | 1.58 (0.85 to NA) | 2.12 (1.18 to 5.22) | 1.79 (1.74 to NA) |
DOR was defined as the time from the first documentation of an objective tumor response (CR or PR) to the first documentation of tumor progression or to death due to any cause, whichever came first. Data are reported based on Kaplan-Meier estimate.
| months | Dose Escalation: GEN1107 8 mg/m^2 | Dose Escalation: GEN1107 15 mg/m^2 | Dose Escalation: GEN1107 30 mg/m^2 | Dose Escalation: GEN1107 37.5 mg/m^2 | Dose Escalation: GEN1107 45 mg/m^2 | Dose Escalation: GEN1107 52.5 mg/m^2 | Dose Escalation: GEN1107 60 mg/m^2 | Dose Escalation: GEN1107 30 mg/m^2 2Q4W |
|---|---|---|---|---|---|---|---|---|
| Duration of Objective Response (DOR) | — | — | — | — | — | — | NA (2.63 to NA) | — |
Plasma samples were taken for analysis of GEN1107 pharmacokinetics. Data are reported for GEN1107 related analytes (total antibody, conjugated monomethyl auristatin E \[MMAE\], unconjugated MMAE).
| day*ng/mL | Dose Escalation: GEN1107 8 mg/m^2 | Dose Escalation: GEN1107 15 mg/m^2 | Dose Escalation: GEN1107 30 mg/m^2 | Dose Escalation: GEN1107 37.5 mg/m^2 | Dose Escalation: GEN1107 45 mg/m^2 | Dose Escalation: GEN1107 52.5 mg/m^2 | Dose Escalation: GEN1107 60 mg/m^2 | Dose Escalation: GEN1107 30 mg/m^2 2Q4W |
|---|---|---|---|---|---|---|---|---|
| Total antibody Cycle 1 Day 1 | 10413.9366 ± 27.0 | 20475.6211 ± 9.2 | 54719.5854 ± 12.3 | 81085.8506 ± 27.1 | 76868.7913 ± 30.6 | 93621.6326 ± 3.1 | 103016.5975 ± 20.7 | — |
| Total antibody Cycle 1 Day 8 | — | — | — | — | — | — | — | 99589.6900 |
| Conjugated MMAE Cycle 1 Day 1 | 355.9793 ± 17.8 | 750.4199 ± 0.6 | 1621.6469 ± 12.3 | 2535.3404 ± 17.6 | 2521.2133 ± 27.5 | 2771.3718 ± 11.5 | 3441.2499 ± 22.1 | — |
| Conjugated MMAE Cycle 1 Day 8 | — | — | — | — | — | — | — | 2612.6760 |
| Unconjugated MMAE Cycle 1 Day 1 | 6.3620 | 11.3990 | 27.4365 ± 77.0 | 21.8609 ± 104.5 | 33.8916 ± 88.1 | 70.7700 | 56.0742 ± 33.8 | — |
| Unconjugated MMAE Cycle 1 Day 8 | — | — | — | — | — | — | — | 29.4870 |
Plasma samples were taken for analysis of GEN1107 pharmacokinetics. Data are reported for GEN1107 related analytes (total antibody, conjugated MMAE, unconjugated MMAE).
| nanograms per milliliter (ng/ml) | Dose Escalation: GEN1107 8 mg/m^2 | Dose Escalation: GEN1107 15 mg/m^2 | Dose Escalation: GEN1107 30 mg/m^2 | Dose Escalation: GEN1107 37.5 mg/m^2 | Dose Escalation: GEN1107 45 mg/m^2 | Dose Escalation: GEN1107 52.5 mg/m^2 | Dose Escalation: GEN1107 60 mg/m^2 | Dose Escalation: GEN1107 30 mg/m^2 2Q4W |
|---|---|---|---|---|---|---|---|---|
| Total antibody Cycle 1 Day 1 | 6706.176 ± 17.5 | 9815.312 ± 12.3 | 18217.621 ± 8.1 | 19896.525 ± 24.6 | 19157.244 ± 25.5 | 26370.367 ± 11.4 | 27602.448 ± 22.6 | 19439.621 ± 13.2 |
| Total antibody Cycle 1 Day 8 | — | — | — | — | — | — | — | 19725.228 ± 25.3 |
| Conjugated MMAE Cycle 1 Day 1 | 184.0 ± 23.7 | 323.8 ± 5.2 | 553.6 ± 4.1 | 616.3 ± 10.5 | 646.2 ± 13.6 | 856.0 ± 8.4 | 952.9 ± 22.0 | 585.1 ± 18.5 |
| Conjugated MMAE Cycle 1 Day 8 | — | — | — | — | — | — | — | 573.8 ± 23.5 |
| Unconjugated MMAE Cycle 1 Day 1 | 0.3675 ± 109.7 | 1.0147 ± 11.5 | 1.8422 ± 75.3 | 1.7929 ± 92.8 | 2.7091 ± 66.7 | 6.0886 ± 15.6 | 4.7850 ± 39.9 | 1.9672 ± 39.8 |
| Unconjugated MMAE Cycle 1 Day 8 | — | — | — | — | — | — | — | 2.2826 ± 6.5 |
Plasma samples were taken for analysis of GEN1107 pharmacokinetics. Data are reported for GEN1107 related analytes (total antibody, conjugated MMAE, unconjugated MMAE).
| days | Dose Escalation: GEN1107 8 mg/m^2 | Dose Escalation: GEN1107 15 mg/m^2 | Dose Escalation: GEN1107 30 mg/m^2 | Dose Escalation: GEN1107 37.5 mg/m^2 | Dose Escalation: GEN1107 45 mg/m^2 | Dose Escalation: GEN1107 52.5 mg/m^2 | Dose Escalation: GEN1107 60 mg/m^2 | Dose Escalation: GEN1107 30 mg/m^2 2Q4W |
|---|---|---|---|---|---|---|---|---|
| Total antibody Cycle 1 Day 1 | 0.0245 ± 2.9 | 0.0563 ± 94.5 | 0.0696 ± 89.9 | 0.0407 ± 65.3 | 0.0765 ± 235.2 | 0.0524 ± 68.3 | 0.0510 ± 65.3 | 0.0397 ± 17.9 |
| Total antibody Cycle 1 Day 8 | — | — | — | — | — | — | — | 0.0390 ± 23.8 |
| Conjugated MMAE Cycle 1 Day 1 | 0.0245 ± 2.9 | 0.0283 ± 17.6 | 0.0277 ± 16.3 | 0.0407 ± 65.3 | 0.0617 ± 253.7 | 0.0524 ± 68.3 | 0.0553 ± 71.0 | 0.0397 ± 17.9 |
| Conjugated MMAE Cycle 1 Day 8 | — | — | — | — | — | — | — | 0.0390 ± 23.8 |
| Unconjugated MMAE Cycle 1 Day 1 | 0.9414 ± 6.8 | 1.9018 ± 5.9 | 3.3200 ± 59.1 | 4.6158 ± 43.1 | 4.1395 ± 100.0 | 4.3798 ± 44.3 | 4.7327 ± 62.3 | 2.9658 ± 1.7 |
| Unconjugated MMAE Cycle 1 Day 8 | — | — | — | — | — | — | — | 3.1393 ± 69.9 |
Plasma samples were taken for analysis of GEN1107 pharmacokinetics. Data are reported for GEN1107 related analytes (total antibody, conjugated MMAE, unconjugated MMAE).
| days | Dose Escalation: GEN1107 8 mg/m^2 | Dose Escalation: GEN1107 15 mg/m^2 | Dose Escalation: GEN1107 30 mg/m^2 | Dose Escalation: GEN1107 37.5 mg/m^2 | Dose Escalation: GEN1107 45 mg/m^2 | Dose Escalation: GEN1107 52.5 mg/m^2 | Dose Escalation: GEN1107 60 mg/m^2 | Dose Escalation: GEN1107 30 mg/m^2 2Q4W |
|---|---|---|---|---|---|---|---|---|
| Total antibody Cycle 1 Day 1 | 1.3793 ± 2.1 | 1.3869 ± 8.7 | 2.0788 ± 19.2 | 3.2138 ± 23.8 | 3.2028 ± 36.3 | 2.0597 ± 14.7 | 2.8470 ± 37.3 | — |
| Total antibody Cycle 1 Day 8 | — | — | — | — | — | — | — | 2.3480 |
| Conjugated MMAE Cycle 1 Day 1 | 1.7719 ± 30.5 | 3.7028 ± 87.2 | 3.6406 ± 48.6 | 4.0874 ± 23.0 | 3.9962 ± 24.6 | 2.9990 ± 11.9 | 3.9973 ± 26.7 | — |
| Conjugated MMAE Cycle 1 Day 8 | — | — | — | — | — | — | — | 3.3720 |
| Unconjugated MMAE Cycle 1 Day 1 | 3.9780 | 3.9990 | 4.9978 ± 21.7 | 6.1131 ± 35.5 | 5.9716 ± 6.3 | 6.5730 | 5.4111 ± 12.2 | — |
| Unconjugated MMAE Cycle 1 Day 8 | — | — | — | — | — | — | — | 5.3300 |
Plasma samples were taken for analysis of GEN1107 pharmacokinetics. Data are reported for GEN1107 related analytes (total antibody, conjugated MMAE, unconjugated MMAE). The number of participants analyzed reflects participants with evaluable PK data at the relevant sampling timepoint. Where 0 participants are reported, this indicates that no participants had evaluable data for that parameter/timepoint or that the assessment was not applicable for the dosing regimen.
| ng/mL | Dose Escalation: GEN1107 8 mg/m^2 | Dose Escalation: GEN1107 15 mg/m^2 | Dose Escalation: GEN1107 30 mg/m^2 | Dose Escalation: GEN1107 37.5 mg/m^2 | Dose Escalation: GEN1107 45 mg/m^2 | Dose Escalation: GEN1107 52.5 mg/m^2 | Dose Escalation: GEN1107 60 mg/m^2 | Dose Escalation: GEN1107 30 mg/m^2 2Q4W |
|---|---|---|---|---|---|---|---|---|
| Total antibody Cycle 1 Day 1 | — | — | — | — | 399.410 | — | 174.910 | — |
| Conjugated MMAE Cycle 1 Day 1 | — | 2.660 | 5.077 ± 97.9 | 8.994 ± 68.9 | 9.627 ± 94.4 | 7.330 | 7.292 ± 55.5 | — |
| Conjugated MMAE Cycle Cycle 1 Day 8 | — | — | — | — | — | — | — | 5.820 |
| Unconjugated MMAE Cycle 1 Day 1 | 0.0350 | 0.0770 | 0.2749 ± 102.7 | 0.2329 ± 79.6 | 0.3632 ± 58.3 | 1.1100 | 0.5415 ± 55.0 | — |
| Unconjugated MMAE Cycle 1 Day 8 | — | — | — | — | — | — | — | 0.3060 |
For participants with ovarian cancer, a CA-125 response per the GCIG criteria was defined as a ≥50% reduction in CA-125 levels from baseline. The following must also have applied: CA-125 levels must have been ≥2.0 times the upper limit of normal (ULN) within 2 weeks before starting treatment, and the CA-125 response must have been confirmed and maintained for at least 28 days. The analysis included participants with ovarian cancer who were evaluable for CA-125 response. Evaluable participants had baseline CA-125 ≥2× the upper limit of normal (ULN) within 14 days before the first dose and at least one post-baseline assessment. Participants who did not meet these criteria were excluded from the analysis. For arms with an overall number analyzed of 0, no participants met the protocol-defined evaluability criteria.
| Participants | Dose Escalation: GEN1107 8 mg/m^2 | Dose Escalation: GEN1107 15 mg/m^2 | Dose Escalation: GEN1107 30 mg/m^2 | Dose Escalation: GEN1107 37.5 mg/m^2 | Dose Escalation: GEN1107 45 mg/m^2 | Dose Escalation: GEN1107 52.5 mg/m^2 | Dose Escalation: GEN1107 60 mg/m^2 | Dose Escalation: GEN1107 30 mg/m^2 2Q4W |
|---|---|---|---|---|---|---|---|---|
| Number of Participants With Cancer Antigen 125 (CA-125) Response Per Gynecological Cancer Intergroup (GCIG) Criteria for Ovarian Cancer | — | — | 0 | 0 | — | 0 | 1 | 0 |
Collected over Up to approximately 1 year, 7 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dose Escalation: GEN1107 8 mg/m^2 | 1/2 (50%) | 0/2 (0%) | 2/2 (100%) |
| Dose Escalation: GEN1107 15 mg/m^2 | 1/2 (50%) | 1/2 (50%) | 2/2 (100%) |
| Dose Escalation: GEN1107 30 mg/m^2 | 2/4 (50%) | 0/4 (0%) | 4/4 (100%) |
| Dose Escalation: GEN1107 37.5 mg/m^2 | 1/5 (20%) | 1/5 (20%) | 5/5 (100%) |
| Dose Escalation: GEN1107 45 mg/m^2 | 4/6 (66.7%) | 2/6 (33.3%) | 5/6 (83.3%) |
| Dose Escalation: GEN1107 52.5 mg/m^2 | 3/4 (75%) | 2/4 (50%) | 4/4 (100%) |
| Dose Escalation: GEN1107 60 mg/m^2 | 7/8 (87.5%) | 4/8 (50%) | 8/8 (100%) |
| Dose Escalation: GEN1107 30 mg/m^2 2Q4W | 2/2 (100%) | 2/2 (100%) | 2/2 (100%) |
| Event | Dose Escalation: GEN1107 8 mg/m^2 | Dose Escalation: GEN1107 15 mg/m^2 | Dose Escalation: GEN1107 30 mg/m^2 | Dose Escalation: GEN1107 37.5 mg/m^2 | Dose Escalation: GEN1107 45 mg/m^2 | Dose Escalation: GEN1107 52.5 mg/m^2 | Dose Escalation: GEN1107 60 mg/m^2 | Dose Escalation: GEN1107 30 mg/m^2 2Q4W |
|---|---|---|---|---|---|---|---|---|
| PneumonitisRespiratory, thoracic and mediastinal disorders | 0/2 | 0/2 | 0/4 | 0/5 | 0/6 | 0/4 | 0/8 | 1/2 |
| EmbolismVascular disorders | 0/2 | 0/2 | 0/4 | 0/5 | 1/6 | 0/4 | 0/8 | 1/2 |
| Rash maculo-papularSkin and subcutaneous tissue disorders | 0/2 | 0/2 | 0/4 | 0/5 | 0/6 | 0/4 | 0/8 | 1/2 |
| Ischaemic strokeNervous system disorders | 0/2 | 1/2 | 0/4 | 0/5 | 0/6 | 0/4 | 0/8 | 0/2 |
| HypercalcaemiaMetabolism and nutrition disorders | 0/2 | 0/2 | 0/4 | 0/5 | 0/6 | 1/4 | 0/8 | 0/2 |
| PeritonitisInfections and infestations | 0/2 | 0/2 | 0/4 | 0/5 | 0/6 | 1/4 | 0/8 | 0/2 |
| Gastroenteritis norovirusInfections and infestations | 0/2 | 0/2 | 0/4 | 1/5 | 0/6 | 0/4 | 0/8 | 0/2 |
| Acute kidney injuryRenal and urinary disorders | 0/2 | 0/2 | 0/4 | 0/5 | 1/6 | 0/4 | 0/8 | 0/2 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/2 | 0/2 | 0/4 | 0/5 | 0/6 | 0/4 | 1/8 | 0/2 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 0/2 | 0/2 | 0/4 | 0/5 | 0/6 | 0/4 | 1/8 | 0/2 |
| Event | Dose Escalation: GEN1107 8 mg/m^2 | Dose Escalation: GEN1107 15 mg/m^2 | Dose Escalation: GEN1107 30 mg/m^2 | Dose Escalation: GEN1107 37.5 mg/m^2 | Dose Escalation: GEN1107 45 mg/m^2 | Dose Escalation: GEN1107 52.5 mg/m^2 | Dose Escalation: GEN1107 60 mg/m^2 | Dose Escalation: GEN1107 30 mg/m^2 2Q4W |
|---|---|---|---|---|---|---|---|---|
| HypokalaemiaMetabolism and nutrition disorders | 0/2 | 2/2 | 0/4 | 2/5 | 1/6 | 1/4 | 2/8 | 1/2 |
| NauseaGastrointestinal disorders | 2/2 | 2/2 | 2/4 | 1/5 | 2/6 | 2/4 | 4/8 | 1/2 |
| Neutrophil count decreasedInvestigations | 0/2 | 1/2 | 3/4 | 2/5 | 2/6 | 2/4 | 5/8 | 0/2 |
| AlopeciaSkin and subcutaneous tissue disorders | 1/2 | 0/2 | 3/4 | 3/5 | 4/6 | 2/4 | 6/8 | 1/2 |
| FatigueGeneral disorders and administration site conditions | 1/2 | 1/2 | 1/4 | 1/5 | 1/6 | 3/4 | 4/8 | 1/2 |
| DysgeusiaNervous system disorders | 0/2 | 0/2 | 0/4 | 3/5 | 0/6 | 0/4 | 0/8 | 0/2 |
| OnychomadesisSkin and subcutaneous tissue disorders | 0/2 | 1/2 | 0/4 | 0/5 | 0/6 | 0/4 | 0/8 | 0/2 |
| Alanine aminotransferase increasedInvestigations | 0/2 | 0/2 | 0/4 | 1/5 | 0/6 | 0/4 | 0/8 | 1/2 |
| KeratitisEye disorders | 1/2 | 0/2 | 0/4 | 1/5 | 1/6 | 1/4 | 2/8 | 0/2 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 0/2 | 0/2 | 0/4 | 0/5 | 0/6 | 0/4 | 0/8 | 1/2 |
All-treated Participants Analysis Set included all participants who received any amount of GEN1107.
| Age, Categorical(Participants) | Dose Escalation: GEN1107 8 mg/m^2 | Dose Escalation: GEN1107 15 mg/m^2 | Dose Escalation: GEN1107 30 mg/m^2 | Dose Escalation: GEN1107 37.5 mg/m^2 | Dose Escalation: GEN1107 45 mg/m^2 | Dose Escalation: GEN1107 52.5 mg/m^2 | Dose Escalation: GEN1107 60 mg/m^2 | Dose Escalation: GEN1107 30 mg/m^2 2Q4W | Total |
|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 2 | 2 | 4 | 3 | 4 | 2 | 4 | 1 | 22 |
| >=65 years | 0 | 0 | 0 | 2 | 2 | 2 | 4 | 1 | 11 |
| Age, Continuous(years) | Dose Escalation: GEN1107 8 mg/m^2 | Dose Escalation: GEN1107 15 mg/m^2 | Dose Escalation: GEN1107 30 mg/m^2 | Dose Escalation: GEN1107 37.5 mg/m^2 | Dose Escalation: GEN1107 45 mg/m^2 | Dose Escalation: GEN1107 52.5 mg/m^2 | Dose Escalation: GEN1107 60 mg/m^2 | Dose Escalation: GEN1107 30 mg/m^2 2Q4W | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 55 ± 2.8 | 59 ± 1.4 | 54.5 ± 10.5 | 61.4 ± 7.1 | 59.5 ± 7.4 | 60.5 ± 14.2 | 65 ± 10.9 | 59 ± 8.5 | 60.3 ± 9.2 |
| Sex: Female, Male(Participants) | Dose Escalation: GEN1107 8 mg/m^2 | Dose Escalation: GEN1107 15 mg/m^2 | Dose Escalation: GEN1107 30 mg/m^2 | Dose Escalation: GEN1107 37.5 mg/m^2 | Dose Escalation: GEN1107 45 mg/m^2 | Dose Escalation: GEN1107 52.5 mg/m^2 | Dose Escalation: GEN1107 60 mg/m^2 | Dose Escalation: GEN1107 30 mg/m^2 2Q4W | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 2 | 2 | 4 | 4 | 2 | 3 | 4 | 2 | 23 |
| Male | 0 | 0 | 0 | 1 | 4 | 1 | 4 | 0 | 10 |
| Race/Ethnicity, Customized(Participants) | Dose Escalation: GEN1107 8 mg/m^2 | Dose Escalation: GEN1107 15 mg/m^2 | Dose Escalation: GEN1107 30 mg/m^2 | Dose Escalation: GEN1107 37.5 mg/m^2 | Dose Escalation: GEN1107 45 mg/m^2 | Dose Escalation: GEN1107 52.5 mg/m^2 | Dose Escalation: GEN1107 60 mg/m^2 | Dose Escalation: GEN1107 30 mg/m^2 2Q4W | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 2 |
| Missing | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 3 |
| Not Hispanic or Latino | 1 | 2 | 4 | 4 | 6 | 4 | 5 | 2 | 28 |
| Race/Ethnicity, Customized(Participants) | Dose Escalation: GEN1107 8 mg/m^2 | Dose Escalation: GEN1107 15 mg/m^2 | Dose Escalation: GEN1107 30 mg/m^2 | Dose Escalation: GEN1107 37.5 mg/m^2 | Dose Escalation: GEN1107 45 mg/m^2 | Dose Escalation: GEN1107 52.5 mg/m^2 | Dose Escalation: GEN1107 60 mg/m^2 | Dose Escalation: GEN1107 30 mg/m^2 2Q4W | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian Indian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian Other | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Chinese | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Japanese | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Malay | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Missing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 2 | 2 | 4 | 5 | 6 | 3 | 8 | 1 | 31 |
| Region of Enrollment(Participants) | Dose Escalation: GEN1107 8 mg/m^2 | Dose Escalation: GEN1107 15 mg/m^2 | Dose Escalation: GEN1107 30 mg/m^2 | Dose Escalation: GEN1107 37.5 mg/m^2 | Dose Escalation: GEN1107 45 mg/m^2 | Dose Escalation: GEN1107 52.5 mg/m^2 | Dose Escalation: GEN1107 60 mg/m^2 | Dose Escalation: GEN1107 30 mg/m^2 2Q4W | Total |
|---|---|---|---|---|---|---|---|---|---|
| China | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| United States | 2 | 2 | 4 | 5 | 6 | 3 | 8 | 2 | 32 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2024 to primary completion in Aug 2025, 19 months.
Results were first posted in Oct 2026, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.